Scinai Immunotherapeutics (SCNI) Competitors $2.94 +0.04 (+1.38%) Closing price 05/21/2025 03:58 PM EasternExtended Trading$2.80 -0.14 (-4.90%) As of 05/21/2025 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock SCNI vs. KPRX, DWTX, ORGS, PHIO, SNSE, BMRA, CELZ, NEUP, ADXN, and ACXPShould you be buying Scinai Immunotherapeutics stock or one of its competitors? The main competitors of Scinai Immunotherapeutics include Kiora Pharmaceuticals (KPRX), Dogwood Therapeutics (DWTX), Orgenesis (ORGS), Phio Pharmaceuticals (PHIO), Sensei Biotherapeutics (SNSE), Biomerica (BMRA), Creative Medical Technology (CELZ), Neuphoria Therapeutics Inc. - Common Stock (NEUP), Addex Therapeutics (ADXN), and Acurx Pharmaceuticals (ACXP). These companies are all part of the "pharmaceutical products" industry. Scinai Immunotherapeutics vs. Kiora Pharmaceuticals Dogwood Therapeutics Orgenesis Phio Pharmaceuticals Sensei Biotherapeutics Biomerica Creative Medical Technology Neuphoria Therapeutics Inc. - Common Stock Addex Therapeutics Acurx Pharmaceuticals Scinai Immunotherapeutics (NASDAQ:SCNI) and Kiora Pharmaceuticals (NASDAQ:KPRX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, profitability, community ranking, dividends, risk and analyst recommendations. Do analysts rate SCNI or KPRX? Kiora Pharmaceuticals has a consensus price target of $10.00, indicating a potential upside of 221.03%. Given Kiora Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Kiora Pharmaceuticals is more favorable than Scinai Immunotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scinai Immunotherapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Kiora Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Which has more volatility and risk, SCNI or KPRX? Scinai Immunotherapeutics has a beta of 2.23, indicating that its stock price is 123% more volatile than the S&P 500. Comparatively, Kiora Pharmaceuticals has a beta of -0.67, indicating that its stock price is 167% less volatile than the S&P 500. Is SCNI or KPRX more profitable? Kiora Pharmaceuticals' return on equity of 21.32% beat Scinai Immunotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Scinai ImmunotherapeuticsN/A N/A -30.48% Kiora Pharmaceuticals N/A 21.32%16.39% Does the MarketBeat Community prefer SCNI or KPRX? Kiora Pharmaceuticals received 18 more outperform votes than Scinai Immunotherapeutics when rated by MarketBeat users. CompanyUnderperformOutperformScinai ImmunotherapeuticsN/AN/AKiora PharmaceuticalsOutperform Votes1875.00% Underperform Votes625.00% Which has preferable earnings & valuation, SCNI or KPRX? Scinai Immunotherapeutics has higher earnings, but lower revenue than Kiora Pharmaceuticals. Kiora Pharmaceuticals is trading at a lower price-to-earnings ratio than Scinai Immunotherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioScinai Immunotherapeutics$658K4.17-$6.50M-$9.57-0.31Kiora Pharmaceuticals$16M0.59-$12.51M-$2.90-1.07 Do institutionals and insiders hold more shares of SCNI or KPRX? 58.4% of Scinai Immunotherapeutics shares are owned by institutional investors. Comparatively, 77.0% of Kiora Pharmaceuticals shares are owned by institutional investors. 60.9% of Scinai Immunotherapeutics shares are owned by insiders. Comparatively, 0.1% of Kiora Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the media prefer SCNI or KPRX? In the previous week, Scinai Immunotherapeutics' average media sentiment score of 0.00 equaled Kiora Pharmaceuticals'average media sentiment score. Company Overall Sentiment Scinai Immunotherapeutics Neutral Kiora Pharmaceuticals Neutral SummaryKiora Pharmaceuticals beats Scinai Immunotherapeutics on 10 of the 15 factors compared between the two stocks. Get Scinai Immunotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SCNI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SCNI vs. The Competition Export to ExcelMetricScinai ImmunotherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.75M$2.93B$5.38B$8.39BDividend YieldN/A1.71%5.21%4.10%P/E Ratio-0.0130.5026.7619.71Price / Sales4.17400.15389.71117.54Price / CashN/A168.6838.2534.62Price / Book-0.303.286.784.50Net Income-$6.50M-$72.17M$3.23B$248.18M7 Day Performance3.16%2.96%1.51%0.23%1 Month Performance36.74%3.25%10.03%12.39%1 Year Performance-14.53%-28.29%16.65%7.07% Scinai Immunotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SCNIScinai ImmunotherapeuticsN/A$2.94+1.4%N/A-22.4%$2.75M$658,000.00-0.0120KPRXKiora Pharmaceuticals2.5765 of 5 stars$3.19flat$10.00+213.5%-38.1%$9.71M$16M-1.1010Positive NewsGap UpDWTXDogwood Therapeutics1.1913 of 5 stars$4.85+1.5%$10.00+106.2%N/A$9.27MN/A-0.745ORGSOrgenesisN/A$1.92-1.8%N/AN/A$9.19M$662,000.000.00150Gap DownPHIOPhio Pharmaceuticals2.948 of 5 stars$1.90+5.0%$4.00+110.5%-73.8%$9.08MN/A-0.1710Positive NewsSNSESensei Biotherapeutics3.9197 of 5 stars$0.36-1.8%$4.25+1,092.5%-77.1%$8.98MN/A-0.3040BMRABiomerica0.1432 of 5 stars$3.49-1.7%N/A-33.3%$8.89M$5.68M-10.2660CELZCreative Medical TechnologyN/A$2.00+1.0%N/A-55.0%$8.77M$11,000.00-0.535NEUPNeuphoria Therapeutics Inc. - Common Stock1.5429 of 5 stars$4.99+1.8%$21.00+320.8%N/A$8.77M$662,715.000.00N/ANews CoverageEarnings ReportADXNAddex Therapeutics1.6667 of 5 stars$8.11+0.1%$30.00+269.9%-5.6%$8.60M$556,045.00-23.8530Gap UpACXPAcurx Pharmaceuticals2.5712 of 5 stars$0.38-3.9%$12.00+3,058.7%-85.3%$8.51MN/A-0.353Analyst Revision Related Companies and Tools Related Companies Kiora Pharmaceuticals Alternatives Dogwood Therapeutics Alternatives Orgenesis Alternatives Phio Pharmaceuticals Alternatives Sensei Biotherapeutics Alternatives Biomerica Alternatives Creative Medical Technology Alternatives Neuphoria Therapeutics Inc. - Common Stock Alternatives Addex Therapeutics Alternatives Acurx Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SCNI) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredTrump + Musk = AI’s turning pointTrump may not code… but he knows how to pick winners. And according to insiders, his administration is prep...True Market Insiders | SponsoredThe Collapse Has Already Started — Your 401(k) Is NextThere's a major heist happening on American wealth in real time. Except this one doesn't involve masks or v...American Hartford Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Scinai Immunotherapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Scinai Immunotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
